Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says

This article was originally published in The Pink Sheet Daily

Executive Summary

One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
Advertisement

Related Content

FDA Drops “Suicidality” Term, Urges Broader Risk Assessment During Development
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Merck To Focus Taranabant Development On Lower Dose
UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
FDA Issues Suicidality Alert On Antiepileptics
Acomplia To Launch In July In Europe For Obesity Indication
Acomplia To Launch In July In Europe For Obesity Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS068023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel